Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 541 of 5804
-
New hope for SMA babies: risdiplam trial launches in newborns
Disease control CompletedThis study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New eczema cream shows promise in large trial
Symptom relief CompletedThis study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Heart stent showdown: FFR vs. angiography for major artery blockage
Disease control Recruiting nowThe primary purpose of the study was to determine whether the 2-year probability of major adverse cardiac events (primary composite outcome) differed significantly between patients who underwent angiography-guided Percutaneous Coronary Intervention(PCI) and those who underwent Fr…
Phase: NA • Sponsor: Seung-Jung Park • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to tackle recurrent brain lymphomas
Disease control Recruiting nowThis study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central…
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gut bacteria swap could disarm superbugs in hospital patients
Disease control Recruiting nowThe purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection. Limited data from prior studies suggest that MT may be an effective tr…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New study tests if fewer radiation sessions can match standard prostate cancer treatment
Disease control Recruiting nowThis study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual e…
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer-Killing virus combined with keytruda shows promise in stubborn tumors
Disease control Recruiting nowThe goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and e…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could an AI-Designed pill take on Hard-to-Treat cancers?
Disease control Recruiting nowThe goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and r…
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New CAR-T therapy aims to tackle Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowDespite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only to further reduce mortality b…
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug targets hidden heart risk in black and hispanic communities
Disease control CompletedStudy CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCV…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a Two-Drug combo supercharge weight loss?
Disease control CompletedThe main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to fight tough kidney cancers
Disease control Recruiting nowBackground: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed. Objective: To test a pair of drugs (sasanlimab and palbociclib) in people with kidney c…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New shot could tame tough eczema Flare-Ups
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Stroke patients may get a second chance with early tirofiban
Disease control Recruiting nowThe purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.
Phase: PHASE3 • Sponsor: Second Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New BCG vaccine could be just as good for bladder cancer
Disease control Recruiting nowThe aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-…
Phase: PHASE3 • Sponsor: Verity Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New hope for Alzheimer's psychosis: ACP-204 safety trial expands
Symptom relief ENROLLING_BY_INVITATIONThis 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
New hope for recurrent prostate cancer: drug combo aims to control PSA without hormone therapy
Disease control Recruiting nowBackground: Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed. Objective: To test a study drug (enzalutamide), both alone and combined with a second drug (PDS01ADC), i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Cord blood cells engineered to fight Hard-to-Treat blood cancers
Disease control Recruiting nowTo determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identified for individual diseases.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Heated milk ladder could speed up allergy tolerance in kids
Disease control Recruiting nowThis interventional study aims to validate an early heated protein introduction protocol in cow's milk allergic children who already developed tolerance towards extensively heated cow's milk, in order to speed up the development of complete cow's milk tolerance. Natural complete …
Phase: NA • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo aims to control CLL in just one year
Disease control Recruiting nowThis study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Phase: PHASE2 • Sponsor: Inhye Ahn • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC